Targeting mTOR-mediated survival signals in anticancer therapeutic strategies.
about
Myc stabilization in response to estrogen and phospholipase D in MCF-7 breast cancer cellsInvolvement of TSC genes and differential expression of other members of the mTOR signaling pathway in oral squamous cell carcinoma.Long-term results of the phase II trial of the oral mTOR inhibitor everolimus (RAD001) in relapsed or refractory Waldenstrom Macroglobulinemia.Survival signals generated by estrogen and phospholipase D in MCF-7 breast cancer cells are dependent on Myc.Phospholipase D-mTOR requirement for the Warburg effect in human cancer cells.Phospholipase D mediates nutrient input to mammalian target of rapamycin complex 1 (mTORC1).Phospholipase D provides a survival signal in human cancer cells with activated H-Ras or K-Ras.Targeting prostate cancer based on signal transduction and cell cycle pathways.Regulation of mTORC1 and mTORC2 complex assembly by phosphatidic acid: competition with rapamycin.Akt-dependent and -independent mechanisms of mTOR regulation in cancerPhosphatidic acid signaling to mTOR: signals for the survival of human cancer cells.A feedback mechanism between PLD and deadenylase PARN for the shortening of eukaryotic poly(A) mRNA tails that is deregulated in cancer cells.Modulation of oxidative stress and tau phosphorylation by the mTOR activator phosphatidic acid in SH-SY5Y cells.Differential dependence of hypoxia-inducible factors 1 alpha and 2 alpha on mTORC1 and mTORC2.Enhancement of apoptotic damage of squamous cell carcinoma cells by inhibition of the mitochondrial DNA repairing system.HIF alpha expression in VHL-deficient renal cancer cells is dependent on phospholipase D.Defective TGF-beta signaling sensitizes human cancer cells to rapamycin.Phospholipase D couples survival and migration signals in stress response of human cancer cells.mTOR-dependent suppression of protein phosphatase 2A is critical for phospholipase D survival signals in human breast cancer cells.Elevated phospholipase D activity in androgen-insensitive prostate cancer cells promotes both survival and metastatic phenotypes.
P2860
Q24304287-B54CD18E-207C-4C5C-92FF-9B8A1C1F2FB4Q33341180-E365532C-916B-4968-B541-CCD864E544E0Q33414529-5C72A76D-43F8-4699-9AE0-17699B7E3921Q33925127-53091B4E-4324-483D-A5C7-1A926DE8828FQ34440418-C9C75C65-9DCF-465B-9AD4-80CB59FE6F55Q35110918-DAF479F4-95B2-40FF-B4A6-7212BC840FAAQ36745757-48119BE6-35BD-45C8-BA4A-86542131733DQ36995054-F47A4EBD-8076-45E0-AB78-7CD2E86BE7F8Q37110578-A58F0662-54A9-4030-BE0A-19B66B245247Q37114404-FF3217B3-A76B-4A76-8B79-6AC3AA463A38Q37380645-D1CAD084-7E79-49B1-BA5E-2FEBEDBDA58AQ37644513-F6CB8B98-16D7-4B62-8747-623B07B172B1Q39555156-07710F8F-A0A0-4B71-8331-D411555B73B5Q39926383-F061216D-FA8C-480E-A8BE-D1C13F91A35FQ39934736-4046446D-1FF2-4C4F-8123-BB62672FA54CQ40052813-FC39BF3A-0B1D-4219-931D-12744A34E5A0Q40093525-BB00DC57-3A5D-479C-B66B-ADE8F28F0CDCQ40295842-0581C8DE-E5F7-421E-947A-35FA5359AB13Q40383681-8966A3C4-BB27-4953-AB28-B816A2B7ED96Q52663167-ABCB2051-79B0-49E1-8E6C-EDA5659D65FB
P2860
Targeting mTOR-mediated survival signals in anticancer therapeutic strategies.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Targeting mTOR-mediated survival signals in anticancer therapeutic strategies.
@ast
Targeting mTOR-mediated survival signals in anticancer therapeutic strategies.
@en
type
label
Targeting mTOR-mediated survival signals in anticancer therapeutic strategies.
@ast
Targeting mTOR-mediated survival signals in anticancer therapeutic strategies.
@en
prefLabel
Targeting mTOR-mediated survival signals in anticancer therapeutic strategies.
@ast
Targeting mTOR-mediated survival signals in anticancer therapeutic strategies.
@en
P2860
P356
P1476
Targeting mTOR-mediated survival signals in anticancer therapeutic strategies.
@en
P2093
David A Foster
P2860
P304
P356
10.1586/14737140.4.4.691
P577
2004-08-01T00:00:00Z